Hemova Medical


Contact Brandon Doan
Title CEO


At Hemova Medical, we are developing solutions to address the end stage renal disease (ESRD) population. Currently, there are over 380,000 patients who depend on routine hemodialysis for the filtration of their blood. Unfortunately, the vascular access sites which allow us to connect them to hemodialysis machines are poorly designed and fail regularly, placing the patient at risk and drastically increasing the cost of care.
At Hemova, we have developed a novel means of access that is less invasive, more robust and economically sensible. Our device will allow hospitals to reduce both upfront and downstream costs while improving clinical outcomes for our patients.